B614FC9C-BFE0-4C15-BB5E-DAF4FA9D11D5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.45992115637319
- age_years
- 23
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.609
- INTERFERON_GAMMA_RESPONSE+0.522
- G2M_CHECKPOINT+0.457
- ALLOGRAFT_REJECTION+0.423
- E2F_TARGETS+0.418
- IL6_JAK_STAT3_SIGNALING+0.410
- IL2_STAT5_SIGNALING+0.388
- CHOLESTEROL_HOMEOSTASIS+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.372
- COMPLEMENT+0.369
Top 10 suppressed
- KRAS_SIGNALING_DN-0.332
- PANCREAS_BETA_CELLS-0.170
- SPERMATOGENESIS-0.123
- HEDGEHOG_SIGNALING-0.049
- UV_RESPONSE_DN-0.035
- MYOGENESIS-0.015
- OXIDATIVE_PHOSPHORYLATION+0.001
- HEME_METABOLISM+0.041
- BILE_ACID_METABOLISM+0.068
- XENOBIOTIC_METABOLISM+0.071
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.943 |
| 2 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.940 |
| 3 | 53018DE1-9557-4181-A0F2-5200013F1CEA | — | — | 0.933 |
| 4 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.932 |
| 5 | SRR934722 | — | — | 0.930 |
| 6 | SRR934949 | — | — | 0.930 |
| 7 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.929 |
| 8 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.927 |
| 9 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.927 |
| 10 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.609 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.522 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.457 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.423 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.418 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.388 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.372 | Inavolisib | — uncovered |
| COMPLEMENT | 0.369 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.367 | Inavolisib | — uncovered |
| APOPTOSIS | 0.356 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.347 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.345 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.343 | Idelalisib | — uncovered |
| COAGULATION | 0.298 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.289 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.279 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.278 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.274 | Inavolisib | — uncovered |